LLL12B, a small molecule STAT3 inhibitor, induces growth arrest, apoptosis, and enhances cisplatin-mediated cytotoxicity in medulloblastoma cells.

LLL12B, a small molecule STAT3 inhibitor, induces growth arrest, apoptosis, and enhances cisplatin-mediated cytotoxicity in medulloblastoma cells.
复制标题

DOI:
10.1038/s41598-021-85888-x
复制
发表时间:
2021-03-22
期刊:
影响因子:
4.6
通讯作者:
Lin J
Lin J
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Chen X;Pan L;Wei J;Zhang R;Yang X;Song J;Bai RY;Fu S;Pierson CR;Finlay JL;Li C;Lin J

文献摘要

参考文献

被引文献

相似文献

信号转导和转录激活因子3(STAT 3)是一种转录因子,也是一种癌基因产物,在肿瘤的发生发展中起着关键作用。因此,直接靶向持续的STAT 3信号转导是一种有吸引力的抗癌策略。本研究的目的是测试一种新型STAT 3小分子抑制剂LLL 12 B在体外抑制髓母细胞瘤细胞和体内抑制肿瘤生长方面的功效。LLL 12 B选择性抑制白细胞介素-6诱导的STAT 3磷酸化,但不抑制INF-γ诱导的STAT 1磷酸化。LLL 12 B还诱导人髓母细胞瘤细胞凋亡。此外,LLL 12 B在体内表现出良好的口服生物利用度和对髓母细胞瘤细胞的肿瘤生长的有效抑制活性。此外,LLL 12 B与顺铂的组合与髓母细胞瘤细胞中的单一药剂处理相比显示出对细胞活力和肿瘤球形成的更大抑制以及对细胞凋亡的诱导。此外,LLL 12 B和顺铂组合在体内表现出比单一疗法更大的成神经管细胞瘤肿瘤生长抑制。本研究支持LLL 12 B是一种新型的髓母细胞瘤治疗药物,LLL 12 B与化疗药物顺铂的组合可能是一种有效的髓母细胞瘤治疗方法。
Signal Transducer and Activator of Transcription 3 (STAT3) is a transcription factor and an oncogene product, which plays a pivotal role in tumor progression. Therefore, targeting persistent STAT3 signaling directly is an attractive anticancer strategy. The aim of this study is to test the efficacy of a novel STAT3 small molecule inhibitor, LLL12B, in suppressing medulloblastoma cells in vitro and tumor growth in vivo. LLL12B selectively inhibited the induction of STAT3 phosphorylation by interleukin-6 but not induction of STAT1 phosphorylation by INF-γ. LLL12B also induced apoptosis in human medulloblastoma cells. In addition, LLL12B exhibited good oral bioavailability in vivo and potent suppressive activity in tumor growth of medulloblastoma cells in vivo. Besides, combining LLL12B with cisplatin showed greater inhibition of cell viability and tumorsphere formation as well as induction of apoptosis comparing to single agent treatment in medulloblastoma cells. Furthermore, LLL12B and cisplatin combination exhibited greater suppression of medulloblastoma tumor growth than monotherapy in vivo. The present study supported that LLL12B is a novel therapeutic agent for medulloblastoma and the combination of LLL12B with a chemotherapeutic agent cisplatin may be an effective approach for medulloblastoma therapy.
DOI: 10.1128/mcb.21.19.6615-6625.2001
发表时间: 2001-10-01
影响因子: 5.3
作者:
Narimatsu, M;Maeda, H;Hirano, T
通讯作者: Hirano, T
DOI: 10.1038/onc.2016.235
发表时间: 2017-02-02
期刊: Oncogene
影响因子: 8
作者:
Garg N;Bakhshinyan D;Venugopal C;Mahendram S;Rosa DA;Vijayakumar T;Manoranjan B;Hallett R;McFarlane N;Delaney KH;Kwiecien JM;Arpin CC;Lai PS;Gómez-Biagi RF;Ali AM;de Araujo ED;Ajani OA;Hassell JA;Gunning PT;Singh SK
通讯作者: Singh SK
DOI: 10.1101/cshperspect.a008656
发表时间: 2013-04-01
影响因子: 7.2
作者:
McIlwain, David R.;Berger, Thorsten;Mak, Tak W.
通讯作者: Mak, Tak W.
DOI: 10.1093/neuonc/nop031
发表时间: 2010-03-01
期刊: NEURO-ONCOLOGY
影响因子: 15.9
作者:
Dunkel, Ira J.;Gardner, Sharon L.;Finlay, Jonathan L.
通讯作者: Finlay, Jonathan L.
DOI: 10.1074/jbc.274.33.22932
发表时间: 1999-08-13
影响因子: 4.8
作者:
Boulares, AH;Yakovlev, AG;Smulson, M
通讯作者: Smulson, M